A fusion peptide combining thymosin alpha-1 and thymopentin was produced in yeast and found to have a plasma half-life of 140 minutes, far longer than thymopentin alone at just 5.6 minutes. The fusion peptide showed stronger immune-boosting activity than either component alone, including greater stimulation of immune cell growth and enhanced macrophage function, making it a promising therapeutic candidate.
Gao, Demin; Zhang, Xulong; Zhang, Jian; Cao, Jichao; Wang, Fengshan